NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
NewAmsterdam Pharma Co N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$20.47+0.64 (+3.23%)
Close on Oct 19, 2026
- Market cap
- $2.53B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$15.93 (−43.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NewAmsterdam Pharma Co N.V. saw revenue fall 88.9% to $7.12M over the twelve months to Jun 30, 2026. Free cash flow was -$143.72M.
Revenue
$7.12M
-88.9% vs. a year earlier
Operating income
-$244.41M
TTM Q2 2026
Free cash flow
-$143.72M
TTM Q2 2026
EPS, diluted
-$2.15
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.53B
- P/E ratio
- –
- Price to sales
- 354.64
- Price to book
- 4.00
- Dividend yield
- –
- Free cash flow yield
- -5.69%
Fundamentals
- Revenue
- $7.12M
- Net income
- -$259.50M
- EPS, diluted
- -$2.15
- Free cash flow
- -$143.72M
- Book value per share
- $5.12
- Diluted shares
- 123M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$7.12M-88.9% YoY
Operating income
-$244.41M
Net income
-$259.50M
EPS, diluted
-$2.15
Free cash flow
-$143.72M
Reported periodTrailing twelve months